Biomarker profiles and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome

Abstract Introduction The risk factors that collectively define metabolic syndrome (MetS) are common in heart failure (HF) patients. More research is needed to elucidate the individual role of MetS pathophysiology HF. Purpose study investigates differences biomarker profiles HF patients with and without MetS. Methods results prevalence was 468 1103 (42.4%) index cohort 615 1433 (42.9%) validation cohort. With a microarray analysis 363 biomarkers, versus were identified. resulting used network analyse underlying pathophysiological mechanisms. profile for showed 43 upregulated 5 downregulated biomarkers In cohort, there 58 3 biomarkers. most significantly shared between two cohorts leptin, fatty acid-binding protein 4, interleukin-1 receptor antagonist, tumour necrosis factor superfamily member 11a, RET proto-oncogene. Network identified 10 pathways 6 all related inflammation. Conclusion Pathophysiological leading likely obesity chronic inflammatory state found these should be validated similar compare outcomes. Several proteins might interesting targets future new treatment options Funding Acknowledgement Type funding sources: None.